In the current retrospective study, we aimed to investigate the clinical efficacies of pembrolizumab as first-line therapy as well as nivolumab monotherapy as subsequent-line treatment and to evaluate the correlations between hematologic parameters and clinical outcomes of different anti-PD-1 therapies in advanced NSCLC patients. Here, PDCD1 is linked to non-small cell lung carcinoma.